Friction-cost method as an alternative to the human-capital approach in calculating indirect costs Howard Birnbaum Editorial 17 September 2012 Pages: 103 - 104
The friction-cost method Werner B. F. BrouwerMarc A. Koopmanschap Current Opinion 17 September 2012 Pages: 105 - 111
The diffusion of health economics knowledge in Europe Gérard de PouvourvillePhilippe UlmannMichael Drummond Leading Article 17 September 2012 Pages: 113 - 120
The case for stratified cost-effectiveness analysis by baseline health-related QOL Joseph Schaafsma Leading Article 17 September 2012 Pages: 121 - 132
Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease Joel W. HayKimberly L. Sterling Original Research Article 17 September 2012 Pages: 133 - 141
Providing systematic guidance in pharmacoeconomic guidelines for analysing costs Philip JacobsArto OhinmaaBruce Brady Original Research Article 17 September 2012 Pages: 143 - 153
Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder José-Luis FernandezStuart MontgomeryClément Francois Original Research Article 17 September 2012 Pages: 155 - 167
Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome Naoki AikawaSeitaro FujishimaTaira Abiru Original Research Article 17 September 2012 Pages: 169 - 181
The impact of anaemia and its treatment on employee disability and medical costs Ernst BerndtWilliam CrownGary H. Lyman Original Research Article 17 September 2012 Pages: 183 - 192
Memantine Greg L. PloskerKatherine A. Lyseng-Williamson Adis Pharmacoeconomic Drug Evaluation 17 September 2012 Pages: 193 - 206